CA2999332A1 - Forme cristalline de 2- (2,6-dichlorophenyl)-1-[(1s,3r)-3-(hydroxymethyl)-5-(3-hydroxy-3-methylbutyl)-1-methyl -3,4-dihydroisoquinolein -2 (1h)-yl)ethanone pour le traitement de la maladie de parkinson - Google Patents
Forme cristalline de 2- (2,6-dichlorophenyl)-1-[(1s,3r)-3-(hydroxymethyl)-5-(3-hydroxy-3-methylbutyl)-1-methyl -3,4-dihydroisoquinolein -2 (1h)-yl)ethanone pour le traitement de la maladie de parkinson Download PDFInfo
- Publication number
- CA2999332A1 CA2999332A1 CA2999332A CA2999332A CA2999332A1 CA 2999332 A1 CA2999332 A1 CA 2999332A1 CA 2999332 A CA2999332 A CA 2999332A CA 2999332 A CA2999332 A CA 2999332A CA 2999332 A1 CA2999332 A1 CA 2999332A1
- Authority
- CA
- Canada
- Prior art keywords
- methyl
- compound
- mmol
- dihydroisoquinolin
- hydroxy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
- C07D217/14—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals
- C07D217/16—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals substituted by oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562245391P | 2015-10-23 | 2015-10-23 | |
US62/245,391 | 2015-10-23 | ||
PCT/US2016/057447 WO2017070068A1 (fr) | 2015-10-23 | 2016-10-18 | Forme cristalline de 2- (2,6-dichlorophényl)-1-[(1s,3r)-3-(hydroxyméthyl)-5-(3-hydroxy-3-méthylbutyl)-1-méthyl -3,4-dihydroisoquinoléin -2 (1h)-yl)éthanone pour le traitement de la maladie de parkinson |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2999332A1 true CA2999332A1 (fr) | 2017-04-27 |
Family
ID=57233858
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2999332A Abandoned CA2999332A1 (fr) | 2015-10-23 | 2016-10-18 | Forme cristalline de 2- (2,6-dichlorophenyl)-1-[(1s,3r)-3-(hydroxymethyl)-5-(3-hydroxy-3-methylbutyl)-1-methyl -3,4-dihydroisoquinolein -2 (1h)-yl)ethanone pour le traitement de la maladie de parkinson |
Country Status (13)
Country | Link |
---|---|
CN (1) | CN108137506A (fr) |
AR (1) | AR106332A1 (fr) |
AU (1) | AU2016341115A1 (fr) |
CA (1) | CA2999332A1 (fr) |
DO (1) | DOP2018000103A (fr) |
EA (1) | EA201890525A1 (fr) |
EC (1) | ECSP18030976A (fr) |
IL (1) | IL257872A (fr) |
MX (1) | MX2018004794A (fr) |
PE (1) | PE20181296A1 (fr) |
PH (1) | PH12018500859A1 (fr) |
TW (1) | TW201725199A (fr) |
WO (1) | WO2017070068A1 (fr) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI725408B (zh) * | 2018-04-20 | 2021-04-21 | 美商美國禮來大藥廠 | 多巴胺d1受體正向異位調節劑 |
SG11202106595VA (en) | 2018-12-18 | 2021-07-29 | Lilly Co Eli | Dose regimens for use of ly3154207 in the treatment of dopaminergic cns disorders |
TWI825323B (zh) | 2019-06-18 | 2023-12-11 | 美商美國禮來大藥廠 | 用於製備2-(2,6-二氯苯基)-1-[(1s,3r)-3-(羥甲基)-5-(3-羥基-3-甲基丁基)-1-甲基-3,4-二氫異喹啉-2(1h)-基]乙烯酮之方法及中間物 |
WO2022192231A1 (fr) | 2021-03-08 | 2022-09-15 | Eli Lilly And Company | Utilisation de mevidalen et d'autres modulateurs allostériques positifs d1 dans le traitement d'hallucinations et de psychose associée à la démence |
CN117337173A (zh) | 2021-03-09 | 2024-01-02 | 伊莱利利公司 | 美维达林和其他d1正向别构调节剂用于减缓帕金森氏病进展的用途 |
CN113264926A (zh) * | 2021-05-31 | 2021-08-17 | 东北林业大学 | 一种牡荆素与利血平的共晶及其制备方法 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5236934A (en) * | 1992-08-26 | 1993-08-17 | E. I. Du Pont De Nemours And Company | 1,2,3,4-tetrahydroisoquinolines useful in the treatment of CNS disorders |
AU2008223145A1 (en) * | 2007-03-01 | 2008-09-12 | Janssen Pharmaceutica N.V. | Tetrahydroisoquinoline compounds as modulators of the histamine H3 receptor |
US20120252853A1 (en) * | 2011-04-01 | 2012-10-04 | H. Lundbeck A/S | Positive allosteric modulators of nicotinic acetylcholine receptor |
JO3316B1 (ar) * | 2013-05-30 | 2019-03-13 | Lilly Co Eli | مركبات 3، 4-داي هيدرو أيزو كوينولين -2(1h)-يل |
-
2016
- 2016-10-13 AR ARP160103122A patent/AR106332A1/es unknown
- 2016-10-14 TW TW105133203A patent/TW201725199A/zh unknown
- 2016-10-18 MX MX2018004794A patent/MX2018004794A/es unknown
- 2016-10-18 PE PE2018000570A patent/PE20181296A1/es not_active Application Discontinuation
- 2016-10-18 AU AU2016341115A patent/AU2016341115A1/en not_active Abandoned
- 2016-10-18 CN CN201680061907.6A patent/CN108137506A/zh active Pending
- 2016-10-18 EA EA201890525A patent/EA201890525A1/ru unknown
- 2016-10-18 CA CA2999332A patent/CA2999332A1/fr not_active Abandoned
- 2016-10-18 WO PCT/US2016/057447 patent/WO2017070068A1/fr active Application Filing
-
2018
- 2018-03-05 IL IL257872A patent/IL257872A/en unknown
- 2018-04-20 DO DO2018000103A patent/DOP2018000103A/es unknown
- 2018-04-20 PH PH12018500859A patent/PH12018500859A1/en unknown
- 2018-04-20 EC ECIEPI201830976A patent/ECSP18030976A/es unknown
Also Published As
Publication number | Publication date |
---|---|
MX2018004794A (es) | 2018-06-19 |
PE20181296A1 (es) | 2018-08-07 |
WO2017070068A1 (fr) | 2017-04-27 |
AU2016341115A1 (en) | 2018-04-12 |
DOP2018000103A (es) | 2018-10-31 |
AR106332A1 (es) | 2018-01-03 |
TW201725199A (zh) | 2017-07-16 |
ECSP18030976A (es) | 2018-05-31 |
IL257872A (en) | 2018-06-03 |
EA201890525A1 (ru) | 2018-09-28 |
CN108137506A (zh) | 2018-06-08 |
PH12018500859A1 (en) | 2018-10-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2016238934B2 (en) | 3,4-dihydroisoquinolin-2(1H)-yl compounds | |
CA2999332A1 (fr) | Forme cristalline de 2- (2,6-dichlorophenyl)-1-[(1s,3r)-3-(hydroxymethyl)-5-(3-hydroxy-3-methylbutyl)-1-methyl -3,4-dihydroisoquinolein -2 (1h)-yl)ethanone pour le traitement de la maladie de parkinson | |
JP7034941B2 (ja) | Lsd1/hdac二重阻害剤としてのシクロプロピル-アミド化合物 | |
CN105764905B (zh) | 新的八氢-环丁二烯并[1,2-c;3,4-c’]二吡咯-2基 | |
JP2019503385A (ja) | Ror−ガンマのモジュレータとしてのベンズイミダゾール誘導体 | |
WO2018181345A1 (fr) | Composé hétérocyclique | |
US20230322797A1 (en) | Solid forms, pharmaceutical compositions and preparation of heteroaromatic macrocyclic ether compounds | |
CA3097692C (fr) | Derives de pyrazo-tetrahydroisoquinoleine en tant que modulateurs positifs du recepteur d1 de la dopamine | |
AU2016369523B2 (en) | Solid forms of substituted 5,6-dihydro-6-phenylbenzo[f]isoquinolin-2-amine compounds | |
WO2016011195A1 (fr) | Formes solides de th-302 et procédés associés | |
WO2021129629A1 (fr) | Inhibiteur de l'amplificateur de l'homologue zeste 2 et son utilisation | |
WO2023078271A1 (fr) | Composé aromatique, son procédé de préparation, intermédiaire de celui-ci, composition pharmaceutique de celui-ci et son utilisation | |
JPH0395160A (ja) | 二環式アミン化合物およびその製造法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request |
Effective date: 20180320 |
|
FZDE | Discontinued |
Effective date: 20191018 |